The Latest Cardiac and Vascular News
– HAVs observed to provide long-term perfusion to patients with critical limb ischemia – 3D Angiograms show mechanical durability of engineered human blood vessels DURHAM, N.C., Jan. 24, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform […]
HAV™ was utilized to treat multiple patients suffering from shrapnel, gunshot wounds, and mine blast injuries DURHAM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, complex tissue […]
— Successful first two HAV implantations in wounded Ukrainian citizens — HAVs were provided under Humacyte’s initiative to assist Ukraine humanitarian medical effort — Provides further real-world evidence of the potential of HAV treatment for trauma DURHAM, N.C., June 21, […]
— Data indicate HAV does not stimulate increase in panel reactive antibodies, an adaptive immune response correlated with increased risk of implant failure — — Data presented today in IMPACT session at American Transplant Congress (ATC) 2022 — DURHAM, N.C., […]
DURHAM, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the first preclinical results of the use of Humacyte’s Human Acellular Vessel™ (HAV) […]
